IGA NEPHROPATHY
Clinical trials for IGA NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new IGA NEPHROPATHY trials appear
Sign up with your email to follow new studies for IGA NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Last-resort access: kidney drug offered outside trials for seriously ill patients
Disease control AVAILABLEThis program provides early access to the drug EXV811 (atrasentan) for people with a serious kidney disease called IgA nephropathy who have no other treatment options and cannot join a clinical trial. It is only available through a doctor's request and aims to help control the di…
Matched conditions: IGA NEPHROPATHY
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 04:01 UTC
-
New drug combo aims to slow kidney disease in IgA patients
Disease control Recruiting nowThis study tests whether combining budesonide and ambrisentan can lower protein in the urine and slow kidney function loss in people with IgA nephropathy, a chronic kidney disease. About 129 adults aged 18–70 with protein in their urine will receive the combo for 36 weeks. The go…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE4 • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated May 17, 2026 03:58 UTC
-
New drug BHV-1400 enters early human testing for kidney disease
Disease control Recruiting nowThis early-stage study tests whether a new drug called BHV-1400 is safe and tolerable for people with IgA nephropathy, a kidney disease. About 20 adults with confirmed IgA nephropathy will receive the drug and be monitored for side effects. The goal is to gather safety data, not …
Matched conditions: IGA NEPHROPATHY
Phase: PHASE1 • Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Can longer treatment tame a kidney disease?
Disease control Recruiting nowThis study looks at whether taking TARPEYO for more than 9 months can further help adults with IgA nephropathy, a kidney disease. About 60 people who have already completed 9 months of TARPEYO will take the drug for another 19 months. Researchers will check urine and blood sample…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE4 • Sponsor: Calliditas Therapeutics AB • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
2000 patients join hunt for early warning signs of kidney failure
Knowledge-focused Recruiting nowThis study follows 2000 people with IgA nephropathy who still have good kidney function. Researchers will test blood and urine samples to find markers that might predict if kidney disease will get worse over time. No new treatments are being tested—the goal is to better understan…
Matched conditions: IGA NEPHROPATHY
Sponsor: Sun Yat-sen University • Aim: Knowledge-focused
Last updated May 17, 2026 04:01 UTC